B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells

References

• Bray FI, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–13.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhang H, Liang R, Xie Z, Luo H, Zeng Y, Xu Y, Wang L, Kong X, Wang K. Colorectal cancer genetic heterogeneity delineated by multi-region sequencing. PLoS One. 2016;11:3.
   Web of Science ®Google Scholar
• Haggar F, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191–197.
   PubMedGoogle Scholar
• Kaur G, Sayegh ET, Larson AR, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014;16:628–636.
   PubMed Web of Science ®Google Scholar
• Ilson DH. Adjuvant therapy in colon cancer: less is more. Lancet Oncol. 2018;19:442–443.
   PubMed Web of Science ®Google Scholar
• Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409–425.
   PubMed Web of Science ®Google Scholar
• Yu TC, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170:548–563.
   PubMed Web of Science ®Google Scholar
• Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Semin Cancer Biol. 2018;52:189–197.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754.
   PubMed Web of Science ®Google Scholar
• Velardi A. NK cell adoptive immunotherapy. Blood. 2005;105:3006.
   Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733.
   PubMed Web of Science ®Google Scholar
• Bonneville M, Obrien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunolo. 2010;10:467–478.
   PubMed Web of Science ®Google Scholar
• Fisher J, Anderson J. Engineering approaches in human gamma delta T cells for cancer immunotherapy. Front Immunol. 2018;9:1409.
   PubMed Web of Science ®Google Scholar
• Willcox CR, Davey MS, Willcox BE. Development and selection of the human Vγ9Vδ2+ T-cell repertoire. Front Immunol. 2018;9:1501.
   PubMed Web of Science ®Google Scholar
• Dar AA, Patil RS, Chiplunkar SV. Insights into the relationship between toll like receptors and gamma delta T cell responses. Front Immunol. 2014;5:366.
   PubMed Web of Science ®Google Scholar
• Presti EL, Pizzolato G, Corsale AM, Caccamo N, Sireci G, Dieli F, Meraviglia S. γδ T cells and tumor microenvironment: from immunosurveillance to tumor evasion. Front Immunol. 2018;9:1395.
   PubMed Web of Science ®Google Scholar
• Simoes AE, Lorenzo BD, Silvasantos B. Molecular determinants of target cell recognition by human γδ T cells. Front Immunol. 2018;9:929.
   PubMed Web of Science ®Google Scholar
• Wu D, Wu P, Wu X, Ye J, Wang Z, Zhao S, Ni C, Hu G, Xu J, Han Y. Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer. OncoImmunology. 2015;4:3.
   Web of Science ®Google Scholar
• Fisher J, Flutter B, Wesemann F, Frosch J, Rossig C, Gustafsson K, Anderson J. Effective combination treatment of GD2-expressing neuroblastoma and Ewing’s sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells. OncoImmunology. 2016;5:1.
   Web of Science ®Google Scholar
• Wang L, Kang F, Shan B. B7‐H3‐mediated tumor immunology: friend or foe? Int J Cancer. 2014;134:2764–2771.
   PubMed Web of Science ®Google Scholar
• Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol. 2001;2:269–274.
   PubMed Web of Science ®Google Scholar
• Shi T, Ma Y, Cao L, Zhan S, Xu Y, Fu F, Liu C, Zhang G, Wang Z, Wang R, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308.
   PubMed Web of Science ®Google Scholar
• Sun J, Chen L, Zhang G, Jiang J, Zhu M, Tan Y, Wang H, Lu B, Zhang X. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 2010;59:1163–1171.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, Negri F, Conte R, Corrias MV, Moretta L. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A. 2004;101:12640–12645.
   PubMed Web of Science ®Google Scholar
• Lee YH, Martinorozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27:1034–1045.
   PubMed Web of Science ®Google Scholar
• Li X, Lu H, Gu Y, Zhang X, Zhang G, Shi T, Chen W. Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression. Exp Cell Res. 2020;386:111719.
   PubMed Web of Science ®Google Scholar
• Hunter S, Willcox CR, Davey MS, Kasatskaya SA, Jeffery HC, Chudakov DM, Oo YH, Willcox BE. Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations. J Hepatol. 2018;69:654–665.
   PubMed Web of Science ®Google Scholar
• Wang R, Ma Y, Zhan S, Zhang G, Cao L, Zhang X, Shi T, Chen W. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-kappaB pathway to induce VEGFA expression. Cell Death Dis. 2020;11:55.
   PubMed Web of Science ®Google Scholar
• Zhou X, Gu Y, Xiao H, Kang N, Xie Y, Zhang G, Shi Y, Hu X, Oldfield E, Zhang X. Combining Vγ9Vδ2 T cells with a lipophilic bisphosphonate efficiently kills activated hepatic stellate cells. Front Immunol. 2017;8:1381.
   PubMedGoogle Scholar
• Fritz JM, Lenardo MJ. Development of immune checkpoint therapy for cancer. J Exp Med. 2019;216:1244–1254.
   PubMed Web of Science ®Google Scholar
• Hoeres T, Holzmann E, Smetak M, Birkmann J, Wilhelm M. PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia. OncoImmunology. 2019;8:1550618.
   PubMed Web of Science ®Google Scholar
• Jogdand GM, Sengupta S, Bhattacharya G, Singh SK, Barik PK, Devadas S. Plasmodium berghei inducible costimulator expressing T cells promote parasitic growth during blood stage ANKA infection. Front Immunol. 2018;9:1041.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhou J, Chen Y, Wei H, Sun R, Tian Z, Peng H. A novel spleen-resident immature NK cell subset and its maturation in a T-bet-dependent manner. J Autoimmun. 2019;105:102307.
   PubMed Web of Science ®Google Scholar
• Bhat SA, Vedpathak DM, Chiplunkar SV. Checkpoint blockade rescues the repressive effect of histone deacetylases inhibitors on γδ T cell function. Front Immunol. 2018;9:1615.
   PubMed Web of Science ®Google Scholar
• Silvasantos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunolo. 2015;15:683–691.
   PubMed Web of Science ®Google Scholar
• Ma J, Ma P, Zhao C, Xue X, Han H, Liu C, Tao H, Xiu W, Cai J, Zhang M. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget. 2016;7:29480–29491.
   PubMedGoogle Scholar
• Qin G, Mao H, Zheng J, Sia SF, Liu Y, Chan P, Lam K, Peiris JSM, Lau YL, Tu W. Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis. 2009;200:858–865.
   PubMed Web of Science ®Google Scholar
• Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008;10(8):842–856.
   PubMed Web of Science ®Google Scholar
• Gertnerdardenne J, Fauriat C, Orlanducci F, Thibult M, Pastor S, Fitzgibbon J, Bouabdallah R, Xerri L, Olive D. The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood. 2013;122:922–931.
   PubMed Web of Science ®Google Scholar
• Cho H, Kim S, Sohn D, Lee M, Park M, Sohn H, Cho H, Kim T. Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vγ9Vδ2 T cells in low levels of IL-2. J Leukoc Biol. 2016;99:521–529.
   PubMed Web of Science ®Google Scholar
• Peters C, Meyer A, Kouakanou L, Feder J, Schricker T, Lettau M, Janssen O, Wesch D, Kabelitz D. TGF-β enhances the cytotoxic activity of Vδ2 T cells. Oncoimmunology. 2019;8:e1522471.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Old LJ, Schreiber RD. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13:95–109.
   PubMed Web of Science ®Google Scholar
• Suh W, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia AEH. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4:899–906.
   PubMed Web of Science ®Google Scholar
• Xu J, Huang B, Xiong P, Feng W, Xu Y, Fang M, Zheng F, Gong F. Soluble Mouse B7-H3 Down-Regulates Dendritic Cell Stimulatory Capacity to Allogenic T Cell Proliferation and Production of IL-2 and IFN-γ. Cell Mol Immunol. 2006;3:235–240.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Narita M, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Aizawa Y, Shinada S. Anti-tumor cytotoxicity of γδ T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol. 2008;25:137–147.
   PubMed Web of Science ®Google Scholar
• Todaro M, Dasaro M, Caccamo N, Iovino F, Francipane MG, Mg F, Meraviglia S, Orlando V, La Mendola C, Gulotta G. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. Default J. 2009;182:7287–7296.
   Google Scholar
• Fournie J, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, Ysebaert L, Laurent G. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol. 2013;10:35–41.
   PubMed Web of Science ®Google Scholar
• Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, Franchini D, Laurent C, Morin R, Lagarde J. Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. OncoImmunology. 2019;8:1554175.
   PubMed Web of Science ®Google Scholar
• Wu K, Zhao H, Xiu Y, Li Z, Zhao J, Xie S, Zeng H, Zhang H, Yu L, Xu B. IL-21-mediated expansion of Vγ9Vδ2 T cells is limited by the Tim-3 pathway. Int Immunopharmacol. 2019;69:136–142.
   PubMed Web of Science ®Google Scholar
• Benyamine A, Loncle C, Foucher E, Blazquez J, Castanier C, Chretien A, Modesti M, Secq V, Chouaib S, Gironella M. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). OncoImmunology. 2018;7:1.
   Web of Science ®Google Scholar
• Van Acker HH, Campillodavo D, Roex G, Versteven M, Smits E, Van Tendeloo V. The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy. Cytokine Growth Factor Rev. 2018;41:54–64.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng L, Aldarouish M, Zhou Z, Pan N, Liu J, Chen F, Wang L. Wnt pathway activator TWS119 enhances the proliferation and cytolytic activity of human γδT cells against colon cancer. Exp Cell Res. 2018;362:63–71.
   PubMed Web of Science ®Google Scholar
• Braza MS, Klein B, Fiol G, Rossi J. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica. 2011;96:400–407.
   PubMed Web of Science ®Google Scholar